title: DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.
abstract: BACKGROUND
  Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling pathways. In patients with advanced colorectal cancer and liver metastases, the effect of vandetanib on tumor vasculature was assessed using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
  
  
  METHODS
  Eligible patients received vandetanib 100 or 300 mg/day. DCE-MRI (iAUC(60 )and K(trans)) was used to quantify the primary endpoints of tumor perfusion and vascular permeability. An exploratory assessment of tumor oxygenation was performed using MRI/T2*. All MRI parameters were measured at baseline (twice) and on days 2, 8, 29 and 57.
  
  
  RESULTS
  Twenty-two patients received vandetanib (n = 10, 100 mg; n = 12, 300 mg). Baseline measurements of iAUC(60 )and K(trans )were reproducible, with low intrapatient coefficients of variation (11% and 24%, respectively). Estimates of mean % changes from baseline were -3.4% (100 mg) and -4.6% (300 mg) for iAUC(60), and -4.6% (100 mg) and -2.7% (300 mg) for K(trans); these changes were not significantly different between doses. The exploratory T2* measurement showed a significant increase at 300 mg versus 100 mg (P = 0.006). Both doses of vandetanib were generally well tolerated; common toxicities were fatigue, rash and diarrhea (majority CTC grade 1 or 2). The pharmacokinetic profile of vandetanib was similar to that observed previously. There were no RECIST-defined objective responses; five patients experienced stable disease >/=8 weeks.
  
  
  CONCLUSIONS
  In this study in patients with advanced colorectal cancer, vandetanib did not modulate gadolinium uptake in tumor vasculature and tissue measured by the DCE-MRI parameters iAUC(60 )and K(trans).
  
  
  BACKGROUND
  NCT00496509 (ClinicalTrials.gov); D4200C00050 (AstraZeneca).
authors: Tumor Biology Centre at the Albert-Ludwigs-University, Freiburg, Germany. mross@tumorbio.uni-freiburg.de
authors: Klaus
authors: K
authors: Mross
authors: Ulrike
authors: U
authors: Fasol
authors: Annette
authors: A
authors: Frost
authors: Robin
authors: R
authors: Benkelmann
authors: Jan
authors: J
authors: Kuhlmann
authors: Martin
authors: M
authors: Büchert
authors: Clemens
authors: C
authors: Unger
authors: Hubert
authors: H
authors: Blum
authors: Jürgen
authors: J
authors: Hennig
authors: Tsveta P
authors: TP
authors: Milenkova
authors: Jean
authors: J
authors: Tessier
authors: Annetta D
authors: AD
authors: Krebs
authors: Anderson J
authors: AJ
authors: Ryan
authors: Richard
authors: R
authors: Fischer